News About Analgesia

Disappointment for Australian innovation

July 23, 2019 | BiotechDispatch

Novartis has quietly scrapped further development of olodanrigan for neuropathic pain. The Swiss company acquired the investigational therapy, also known as EMA401, through its US$200 million acquisition of Spinifex Pharmaceuticals in 2015.

Back to top

America on opioids: 76B pills

July 18, 2019 | LinkedIn

Ten of America's largest drug companies are responsible for releasing 76 billion oxycodone and hydrocodone pain pills from 2006 through 2012, according to previously unreleased data obtained by The Washington Post. These companies, including Walgreens, CVS and Walmart, are being sued in federal court by nearly 2,000 cities, towns and counties claiming they plotted to "flood [America] with opioids." Meanwhile, the number of U.S. deaths tied to drug overdoses fell last year for the first time in almost 30 years, according to the CDC.

Back to top

UC Davis begins study of new pain reliever in horses with chronic lameness

June 28, 2019 | UC Davis

A study is underway at the Center for Equine Health to evaluate a promising new pain reliever in horses with chronic lameness due to joint pain. This effort, led by Dr. Robert Brosnan, a professor in the School of Veterinary Medicine’s Department of Surgical and Radiological Sciences, is supported by a grant from the Equine Tribute and Memorial Fund through the Center for Equine Health. Dr. Brosnan and his team in the Department of Veterinary Anesthesiology and the JD Wheat Veterinary Orthopedic Research Laboratory are collaborating to evaluate a new painkiller that was discovered at the UC Davis School of Veterinary Medicine and compare its effectiveness with a standard treatment and a placebo in horses with chronic lameness.

Back to top

Task force calls for 'individualized, patient-centered approach' to pain management

May 30, 2019 | FierceHealthcare

Physicians treating patients with acute pain should focus on using a multimodal approach that includes medications, nerve blocks, physical therapy and other modalities, according to a federal task force's final report on acute and chronic pain management best practices (PDF) released Thursday. At the same time, doctors treating patients with chronic pain should look to a multidisciplinary approach across various fields. That could include medications, restorative therapies like physical therapy, cognitive therapies and complementary or integrative health.

Back to top

Chemists ID possible addiction-free pain reliever

May 16, 2019 | Phys.org

Ken Hsu, a chemistry professor at the University of Virginia, and his graduate student, Myungsun Shin, has identified an enzyme that "chews up fat" molecules to produce chemical signals that control inflammation. The naturally occurring enzyme, called diacylglycerol lipase-beta, or DAGL-beta, is a possible new drug target for reducing pain. Hsu developed, during his postdoctoral training, selective molecules that inhibit DAGL-beta and reduce inflammation, similarly to aspirin and other non-steroidal anti-inflammatory drugs, or NSAIDS. However, unlike NSAIDs, DAGL-beta inhibitors can provide pain relief without gastrointestinal toxicity in preclinical models when used over a long term. And unlike opioids, DAGL-beta inhibitors do not exhibit addictive properties.

Back to top